AD-214
- Generic Name
- AD-214
- Drug Type
- Biotech
A Study to Compare PK, PD and Safety of the AD-214 and AD-2141
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT05062876
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole
Phase 1
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT04622358
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole
Phase 1
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04494243
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath